Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/94249
Title:
Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy.
Authors:
Illidge, Timothy M ( 0000-0003-3191-7324 ) ; Bayne, Mike; Brown, Nicholas S; Chilton, Samantha; Cragg, Mark S; Glennie, Martin J; Du, Yong; Lewington, Valerie; Smart, James; Thom, James; Zivanovic, Maureen; Johnson, Peter W
Abstract:
The effect of induction therapy with multiple doses of rituximab on the subsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown. We evaluated a novel protocol using 4 weekly infusions of 375 mg/m(2) rituximab followed by 2 fractions of (131)I-rituximab, preceded by a 100-mg/m(2) predose of rituximab, in relapsed indolent B-cell lymphoma. Induction therapy with rituximab significantly increased the effective half-life of (131)I-rituximab (P = .003) and high serum levels of rituximab after induction therapy correlated with increased effective half-life of the radioimmunoconjugate (P = .009). Patients with large tumor burdens experienced significant increases in the effective half-life of (131)I-rituximab between delivery of the first and second fractions (P = .007). Induction therapy with multiple doses of rituximab did not appear to compromise the clinical efficacy or increase toxicity of subsequent (131)I-rituximab radioimmunotherapy. The overall response rate was 94%, with complete response rate 50%. The median time to progression was 20 months, significantly longer than for the last qualifying chemotherapy (P = .001). Fractionation of (131)I-rituximab allowed cumulative whole-body doses of more than 120 cGy, approximately 60% greater than those previously achieved with a single administration of a murine radioimmunconjugate, to be delivered without significant hematologic toxicity.
Affiliation:
School of Cancer and Imaging Sciences, University of Manchester, Manchester, UK. tmi@manchester.ac.uk
Citation:
Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. 2009, 113 (7):1412-21 Blood
Journal:
Blood
Issue Date:
12-Feb-2009
URI:
http://hdl.handle.net/10541/94249
DOI:
10.1182/blood-2008-08-175653
PubMed ID:
19074729
Type:
Article
Language:
en
ISSN:
1528-0020
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorIllidge, Timothy Men
dc.contributor.authorBayne, Mikeen
dc.contributor.authorBrown, Nicholas Sen
dc.contributor.authorChilton, Samanthaen
dc.contributor.authorCragg, Mark Sen
dc.contributor.authorGlennie, Martin Jen
dc.contributor.authorDu, Yongen
dc.contributor.authorLewington, Valerieen
dc.contributor.authorSmart, Jamesen
dc.contributor.authorThom, Jamesen
dc.contributor.authorZivanovic, Maureenen
dc.contributor.authorJohnson, Peter Wen
dc.date.accessioned2010-03-15T16:39:37Z-
dc.date.available2010-03-15T16:39:37Z-
dc.date.issued2009-02-12-
dc.identifier.citationPhase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. 2009, 113 (7):1412-21 Blooden
dc.identifier.issn1528-0020-
dc.identifier.pmid19074729-
dc.identifier.doi10.1182/blood-2008-08-175653-
dc.identifier.urihttp://hdl.handle.net/10541/94249-
dc.description.abstractThe effect of induction therapy with multiple doses of rituximab on the subsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown. We evaluated a novel protocol using 4 weekly infusions of 375 mg/m(2) rituximab followed by 2 fractions of (131)I-rituximab, preceded by a 100-mg/m(2) predose of rituximab, in relapsed indolent B-cell lymphoma. Induction therapy with rituximab significantly increased the effective half-life of (131)I-rituximab (P = .003) and high serum levels of rituximab after induction therapy correlated with increased effective half-life of the radioimmunoconjugate (P = .009). Patients with large tumor burdens experienced significant increases in the effective half-life of (131)I-rituximab between delivery of the first and second fractions (P = .007). Induction therapy with multiple doses of rituximab did not appear to compromise the clinical efficacy or increase toxicity of subsequent (131)I-rituximab radioimmunotherapy. The overall response rate was 94%, with complete response rate 50%. The median time to progression was 20 months, significantly longer than for the last qualifying chemotherapy (P = .001). Fractionation of (131)I-rituximab allowed cumulative whole-body doses of more than 120 cGy, approximately 60% greater than those previously achieved with a single administration of a murine radioimmunconjugate, to be delivered without significant hematologic toxicity.en
dc.language.isoenen
dc.subjectHaemoglobinen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshDisease-Free Survival-
dc.subject.meshDose-Response Relationship, Radiation-
dc.subject.meshFemale-
dc.subject.meshHemoglobins-
dc.subject.meshHumans-
dc.subject.meshIodine Radioisotopes-
dc.subject.meshLymph Nodes-
dc.subject.meshLymphoma, B-Cell-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeutrophils-
dc.subject.meshPlatelet Count-
dc.subject.meshRadioimmunotherapy-
dc.subject.meshSpleen-
dc.titlePhase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy.en
dc.typeArticleen
dc.contributor.departmentSchool of Cancer and Imaging Sciences, University of Manchester, Manchester, UK. tmi@manchester.ac.uken
dc.identifier.journalBlooden

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.